• IP And Technology Transfer

Special report: patents and SPCs post-Brexit – pharma’s big opportunity?

Have you reviewed your post-Brexit patent and SPC pharma strategies? In a 32-page special report pharma patent specialists Garreth Duncan and Jennifer O'Farrell shine a spotlight on the opportunities and challenges that the pharma industry faces.

Cancer Research UK launches new ‘cancer tech accelerator’ programme

Cancer Research UK and Capital Enterprise, together with Roche UK, have launched the Cancer Tech Accelerator programme to support innovative technologies that can advance the early detection, diagnosis, monitoring or treatment of cancer.

The best in AI appointed at Norwich Research Park

Scientists across Norwich Research Park institutes are part of a major integrated UK research-industry programme led by The Alan Turing Institute, seeking out the best talent in AI and data science, developing bioscience leaders and supporting the UK economy.

WuXi AppTec Completes Acquisition of OXGENE to Further Strengthen Cell and Gene Therapy Service Offerings for Global Customers

WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies

Accelerate@Babraham Start-up Programme underway with four new life science start-ups taking part in the five month programme

Benefits of the programme include access to the Babraham Research Campus bio-incubator facilities, an extended programme of mentoring and support and £10k undiluted funding

CombiGene and CGT Catapult collaboration completes development of quality control analytical assays for clinical production of CombiGene’s AAV-based gene therapy for the treatment of epilepsy

The extensive and advanced work to develop the critical analytical assays needed for quality control in the manufacture of the AAV1 based gene therapy product CG01 has now been completed in a collaboration between CombiGene and CGT Catapult. CombiGene will now integrate the analytical assays into its production process, taking it another step closer to its final large scale production design for clinical trials and commercial distribution.

CGT Catapult Annual Review 2020 highlights impact on growth and productivity in the UK cell and gene therapy industry

The 2020 annual report released today presents Cell and Gene Therapy Catapult's achievements, collaborations and initiatives from the past year and their impact in enhancing growth, productivity and supporting the development and commercialisation of cell and gene therapies.

Eisai pledges its support for the Babraham Research Campus’ Accelerate@Babraham initiative; supporting early-stage science and new life science companies within the cluster

The Babraham Research Campus is delighted to confirm Eisai as the latest high-profile organisation to provide financial and mentoring support for its Accelerate@Babraham initiative. Eisai join AstraZeneca, LifeArc and Mundipharma in providing funding towards the continued development of the bio-incubator programme

Fieldfisher Life Sciences sector group mobilises to offer pro bono legal advice for COVID-19

Fieldfisher are delighted to announce that their pan-European Life Sciences sector group have mobilised to show support for life science companies contributing efforts towards global pandemic COVID-19.

UCL supports worldwide dissemination of free-to-access manufacturing instructions for COVID-19 breathing aids

Governments across the world, healthcare providers and device manufacturers can now request a free of charge licence to the design and manufacturing files of a breathing aid developed by UCL, UCLH and Mercedes-AMG High Performance Powertrains (Mercedes-AMG HPP) to support healthcare systems preparing for the Covid-19 pandemic.